Lipitor

Atorvastatin, the active ingredient in Lipitor, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated cholesterol and triglyceride levels and is used in patients with primary hyperlipidaemia or at risk of cardiovascular disease.

GNH USA supplies Lipitor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipitor is indicated for disorders of lipid metabolism and for reducing cardiovascular risk. - Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol levels. - Mixed dyslipidemia: lowers triglycerides and raises high‑density lipoprotein (HDL) cholesterol. - Cardiovascular event prevention: decreases the incidence of myocardial infarction, stroke and related events in patients with established risk factors.

Atorvastatin may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Elevated liver enzymes: transient increase in ALT or AST. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible renal impairment. - Hepatotoxicity: marked elevation of liver transaminases or hepatitis. - Severe allergic reactions: rash, angioedema or anaphylaxis. - New‑onset diabetes mellitus: hyperglycaemia reported in some patients.

Before initiating atorvastatin therapy, several precautionary measures should be considered to ensure safe use. - Liver function assessment: obtain baseline ALT/AST and monitor periodically. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Concomitant muscle disorders: assess for myopathy risk in patients with hypothyroidism or prior statin intolerance. - Drug interactions: review concomitant medications that may increase statin exposure, such as strong CYP3A4 inhibitors. - Renal impairment: adjust monitoring in patients with severe renal dysfunction. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Atorvastatin interacts with several medicines that can alter its plasma concentration or increase the risk of adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors): may cause dangerous increases in atorvastatin levels. - Gemfibrozil and other fibrates: heighten risk of myopathy and rhabdomyolysis. - Cyclosporine: significantly raises statin exposure, increasing muscle toxicity.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may modestly reduce absorption. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Digoxin: slight increase in serum concentrations observed. - Niacin: combined therapy can increase risk of liver enzyme elevations.